This inventor holds 1 USPTO granted patent and 2 published patent applications and 1 EPO patent. Top assignee: Hoffmann-La Roche Inc.. Active years: 2025.
Company Filing History:
Years Active: 2025
Title: Angelina Wallier - Innovator in Hepatitis B Research
Introduction
Angelina Wallier is a prominent inventor based in Basel, Switzerland. She is currently associated with F. Hoffmann-La Roche AG, a leading global healthcare company. Although she has not yet been granted any patents, her work focuses on innovative therapeutic agents for the treatment of hepatitis B virus (HBV) infection.
Latest Patent Applications
Angelina Wallier has made significant contributions through her latest patent applications. One of her notable applications is titled "Pyrrolo[2,3-b]pyrazine Compounds as CCCDNA Inhibitors for the Treatment of Hepatitis B Virus (HBV) Infection." This invention relates to novel therapeutic agents that target viral covalently closed circular DNA (cccDNA), which is a critical barrier to curing HBV. The compounds described in this application are highly potent against HBV infection and offer improved therapy options, particularly for chronic HBV infection and HBV rebound. Another important application is "Oligonucleotides for Modulating RTEL1 Expression." This invention focuses on RTEL1 inhibitors for treating chronic HBV infection, aiming to destabilize cccDNA and reduce RTEL1 mRNA through antisense oligonucleotides.
Conclusion
Angelina Wallier is making strides in the field of hepatitis B research with her innovative patent applications. Her work has the potential to significantly impact the treatment of HBV infection and improve patient outcomes.